Market Overview

UPDATE: Piper Jaffray Raises PT to $69 on Jazz Pharmaceuticals; Growth Visibility is Solid

Share:
Related JAZZ
Benzinga's Top Upgrades, Downgrades For May 15, 2017
Earnings Scheduled For May 9, 2017

Piper Jaffray maintained Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Overweight and raises the price target from $65.00 to $69.00.

Piper Jaffray commented, "JAZZ remains our top mid-cap spec pharma pick for 2013, with strong visibility on consistent long-term double-digit EPS growth, high barriers for potential Xyrem generics, all in the context of a 2013 P/E of only 10x. Further, with JAZZ still committed to additional acquisitions of commercial or near-commercial assets, and a strong balance sheet ($387M in cash at YE2012) and potentially more than $400M in operating cash flow generation in 2013, the company is well positioned to execute on a transaction that provides near-term earnings accretion and further revenue diversification in our view."

Jazz Pharmaceuticals closed at $56.83 on Tuesday.

Latest Ratings for JAZZ

DateFirmActionFromTo
May 2017RBC CapitalInitiates Coverage OnTop Pick
Apr 2017MizuhoDowngradesBuyNeutral
Feb 2017Evercore ISI GroupInitiates Coverage OnBuy

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings

 

Related Articles (JAZZ)

View Comments and Join the Discussion!